Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117555 | 0.87 | SIRT2 (0.49) | SIRT2CTSLHTRA1 | |
| SCHEMBL22117554 | 0.87 | SIRT2 (0.49) | SIRT2CTSLHTRA1 | |
| SCHEMBL28925221 | 0.85 | SIRT2 (0.47) | SIRT2CTSLHTRA1 | |
| SCHEMBL28925220 | 0.85 | SIRT2 (0.47) | SIRT2CTSLHTRA1 | |
| SCHEMBL31679027 | 0.84 | KMT2A (0.48) | KMT2ASIRT2CTSLHDAC1HDAC2 | |
| SCHEMBL31679024 | 0.84 | DPP8 (0.49) | SIRT2CTSL | |
| SCHEMBL16217863 | 0.82 | KMT2A (0.58) | KMT2APTPN1TLR2 | |
| SCHEMBL17919592 | 0.82 | KMT2A (0.61) | KMT2ASIRT2TLR2 | |
| SCHEMBL13495919 | 0.82 | KMT2A (0.61) | KMT2ASIRT2TLR2 | |
| SCHEMBL8823890 | 0.81 | FOLH1 (0.62) | KMT2ASIRT2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | KMT2A 4583/4885SIRT2 1556/4885CTSL 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.